Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

BACKGROUND: Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Goadsby, Peter J, Tepper, Stewart J, Watkins, Paul B, Ayele, Girma, Miceli, Rosa, Butler, Matthew, Severt, Lawrence, Finnegan, Michelle, Szegedi, Armin, Trugman, Joel M, Jakate, Abhijeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900570/
https://www.ncbi.nlm.nih.gov/pubmed/31537107
http://dx.doi.org/10.1177/0333102419869918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900570/
https://www.ncbi.nlm.nih.gov/pubmed/31537107
http://dx.doi.org/10.1177/0333102419869918

Ejemplares similares